Fund Companies Rights Offerings Managed Distributions Leveraged Funds IPOs Asset Classes CEF Advisors

My Fund Comparison
Initilizing list...

Tekla Healthcare Investors  as of 07/31/2015

NYSE / HQH Asset Class:  Sector Equity Funds 1 YR Lipper Avg:  2.05%

Growth of $10K

Avg Annual Total Return %
  10 YR 5 YR 1 YR YTD
Market Return 15.46% 36.49% 44.37% 20.86%
Lipper Pct. Rank 13 19 15 18
NAV Return 14.50% 31.32% 40.50% 20.37%
Lipper Pct. Rank 13 19 15 12
Premium/Discount History

10 YR Avg 5 YR Avg YTD Avg
-7.793% -5.694% 2.520%

NAV $36.54 Market Price $36.64
Net Change $0.21 Market Change $0.63
Premium/Discount 0.27%
1 YR NAV Return 40.495%
1 YR NAV Rank 15
12-Mo Yield as of 6/30/2015 Yield Def
Income Only Yield 0.00%
Distribution Yield (Market) 6.92%
Managed Distribution Plan 
Most Recent Income Dividend $0.680
Ex-Div Date 5/22/2015
Most Recent Cap Gain Dividend $0.530
Ex-Div Date 2/27/2014
Dividend Frequency Quarterly
YTD Dividends $1.310
YTD Capital Gains --
Inception Date 4/23/1987
Fund Advisor Tekla Capital Management LLC
Manager & Tenure Team Managed
Phone 800-451-2597
Total Net Assets (mil) as of 6/30/2015 $1,306.1
% Leveraged Assets as of 9/30/2014 --
Portfolio Turnover --
Mgmt Fees 0.960%
Expense Ratio 1.130%
Fund Objective
The Fund seeks long-term capital appreciation by investing primarily in securities of companies in the health services and medical technology (health care) industries ("Health care Companies").
Top Holdings (as of 12/31/2014)
Celgene Corp ORD 9.76%
Gilead Sciences Inc ORD 8.25%
Vertex Pharmaceuticals Inc ORD 5.17%
Biogen Inc ORD 4.87%
Alexion Pharmaceuticals Inc ORD 4.83%
Regeneron Pharmaceuticals Inc ORD 4.78%
Actavis PLC ORD 4.41%
Amgen Inc ORD 3.41%
Incyte Corp ORD 3.26%
Biomarin Pharmaceutical Inc ORD 3.23%
Top Sectors (as of 12/31/2014)
Health Care 82.71%
Non Classified Equity 5.88%
Technology 2.05%
Consumer Services 1.24%

Image Map


Aberdeen Closed-End TV

CEF Connect


National Association of
Publicly Traded Partnerships


Seeking Alpha CEF Articles
SySys Logo

Lipper Logo
Powered by a SySys data & content management system.

© Thomson Reuters 2011. All rights reserved. Any copying, republication or redistribution of Lipper, a Thomson Reuters company, content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper, a Thomson Reuters company. Lipper, a Thomson Reuters company shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.